This work describes the tailored design, green synthesis and characterization of noble metal (Pt, Ag and Au) nanoparticles (NPs) using Sapinduss Mukkorossi fruit extract (SMFE) and its signal NP collision signal response, based on the principle of the electrocatatlytic amplication (EA) method. Here, the SMFE can act as both the reducing and the capping agent for the fabrication of noble nanometals. The SMFE-capped NPs was available for the observation of a single NP collision signal. Two general types of current response were observed: a staircase current response for the Pt or Au NPs, and a blip/spike current response for Ag NPs. These results demonstrated that the eco-friendly synthesized SMFE-capped NPs maintained their electrocatalytic activity, therefore they can be used for the single NP experiments and place an arena for future biosensing applications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956323 | PMC |
| http://dx.doi.org/10.3390/nano9121695 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Dexamethasone Intravitreal Injection in Diabetic Patients Undergoing Cataract Surgery: an updated literature review.
Retina
January 2025
Ophthalmology Clinic, Department of Biomedical Sciences, University of Messina, Italy.
Purpose: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema (DME) in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome.
Methods: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and post-operatively for DME in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy.
SAFETY, PHARMACOKINETICS, AND CLINICAL EFFICACY OF ADS051, A NEUTROPHIL MODULATOR, IN ULCERATIVE COLITIS: RESULTS OF A RANDOMIZED PHASE 1B TRIAL.
Am J Gastroenterol
December 2024
Adiso Therapeutics, Inc, Concord, Massachusetts, USA.
Objectives: Ulcerative colitis (UC) is characterized by colonic inflammation, with neutrophils playing a key role in UC activity, prognosis, and response to therapies. Current UC therapeutics can have significant side effects and limited efficacy. ADS051 is a novel, oral, gut-restricted small molecule that modulates neutrophil migration and activation without in vitro suppression of T-cell activation.
View Article and Find Full Text PDFRome IV functional defecation disorder: time for a change in symptom criteria for improved clinical relevance?
Am J Gastroenterol
December 2024
Faculty of Medicine and Health, University of Sydney, Camperdown, NSW.
Introduction: Defecatory disorders are common affecting up to 8% of the population. Rome IV diagnostic criteria are used to define this condition and therefore select patients for the gold standard therapy, anorectal biofeedback. The aim of this study was to test the current Rome IV FDD criteria in a real-world population by utilizing the response to biofeedback as a validation tool.
View Article and Find Full Text PDFThe Effect of Denosumab on Pain and Radiological Improvement in Giant Cell Tumours of the Spine in the Acute Setting.
Global Spine J
January 2025
Department of Spinal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Study Design: Retrospective Cohort Study.
Objectives: The current recommended treatment for Giant Cell Tumour (GCT) of the spine is en bloc excision. Denosumab is a monoclonal antibody reducing osteoclast activity that shows promising results when used as a neo - adjuvant treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!